Intellia Therapeutics price target raised to $30 from $25 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $25 and keeps a Buy rating on the shares after the FDA lifted the clinical hold on the company’s Phase 3 MAGNITUDE study. The firm believes the “modest” share reaction can be attributed to investor concerns about demand in light of the safety event, despite the relatively low rate of severe adverse events from liver toxicity.